POSC.ob ..News follows ..
Positron PET Device Approved in Canada
Wednesday March 22, 11:39 am ET
HOUSTON--(BUSINESS WIRE)--March 22, 2006--Positron Corporation (OTCBB:POSC - News) today announced that the Company has recently received approval from Health Canada to use Positron's mPower PET scanner in oncology and cardiology clinical trials in Canada. Positron is developing a broad range of applications and upgrades to its mPower line and will be rapidly expanding the approved uses of its mPower product in Canada.
ADVERTISEMENT
Positron is well positioned to take advantage of Health Canada's approval of Positron's PET device by offering its mPower product to Canadian health care providers as a more cost-effective solution to the more traditionally expensive PET and PET/CT products currently available in the marketplace. Positron will comply with Health Canada to provide cost effective studies to support wide spread dissemination across all provinces.
Positron President, Joe Oliverio states: "This represents a continuation of our business strategy in Positron to be a global PET provider that will deliver an affordable medical device with superior software solutions catered to markets that possess limited healthcare resource dollars although demand excellent quality medical care. We believed for a long time that the Canadian market would be ideal for widespread use of PET scanning since many studies have shown to reduce overall healthcare expenditures to the government payers while improving patient outcomes."
About Positron
Positron Corporation designs, manufactures, markets and supports advanced medical imaging devices utilizing positron emission tomography (PET) technology under the trade name POSICAM(TM) systems. POSICAM(TM) systems incorporate patented and proprietary software and technology for the diagnosis and treatment of patients in the areas of cardiology, oncology and neurology. Positron Corporation offers unique combination of low cost technology and disease specific software solutions differentiating themselves from all other medical device manufacturers. POSICAM(TM) systems are in use at leading medical facilities, including the University of Texas -- Houston Health Science Center; The Heart Center of Niagara in Niagara Falls, New York; Beth Israel, New York; Emory Crawford Long Hospital Carlyle Fraser Heart Center in Atlanta; and Nishidai Clinic (Diagnostic Imaging Center) in Tokyo. Additional information may be found at www.positron.com.
Forward Looking Statements
Certain statements in this release, and other written or oral statements made by the Company, including the use of the words "expect," "anticipate," "estimate," "project," "forecast," "outlook," "target," "objective," "plan," "goal," "pursue," "on track," and similar expressions, are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward looking statements are subject to known and unknown risks, uncertainties and other factors that may cause actual results, performance, or achievements of the company to be different from those expressed or implied. The Company assumes no obligation and does not intend to update these forward looking statements. Among the important factors that could cause actual results to differ materially from those indicated by such forward looking statements include, without limitation: competitive and general economic conditions, adverse effects of litigation, the timely development and acceptance of services, significant changes in the competitive environment, the failure to generate or the loss of significant numbers of customers, the loss of senior management, increased government regulation or the company's failure to integrate its acquired companies to achieve the synergies and efficiencies described in the "Management's Discussion and Analysis" section of the Company's Form 10-KSB and other reports and filings with the Securities and Exchange Commission, which may be revised or supplemented in subsequent reports on SEC Forms 10-QSB and 8-K.
For further information please contact Positron Corporation at (281) 492-7100.
Contact:
Positron Corporation
Joseph Oliverio, 716-989-4411
Source: Positron Corporation
Email Story
Set News Alert
Print Story
Related Quote
AI
